PT - JOURNAL ARTICLE AU - Okonko, IO AU - Shaibu, N TI - EVIDENCE OF HIV/HCV COINFECTION AMONG PEOPLE LIVING WITH HIV/AIDS ATTENDING FEDERAL MEDICAL CENTRE, YENAGOA, NIGERIA AID - 10.1101/2023.03.08.23286986 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.08.23286986 4099 - http://medrxiv.org/content/early/2023/03/12/2023.03.08.23286986.short 4100 - http://medrxiv.org/content/early/2023/03/12/2023.03.08.23286986.full AB - Coinfection of hepatitis C (HCV) may compromise antiretroviral therapy (ART) in Nigeria. In this study, we evaluated the seroprevalence of HIV/HCV coinfection in people living with HIV/AIDs (PLWHA) receiving ART and associated factors. Patients were selected from HIV-1-infected patients enrolled in National HAART Cohort at Federal Medical Centre in Yenagoa, Nigeria. Following the manufacturer’s instructions, medical assessments and anti-HCV antibody serology were obtained for analysis with an ELISA kit (Dia. Pro). A total of 4 of 104 PLWHA tested were anti-HCV antibody positive (4.0%). HIV/HCV coinfections were higher in age groups ≥41 years (4.4%), males (7.0%), CD4 counts 350-499 cells/μl (7.1%) and PVL ≥1000 copies/ml (10.0%). CD4 counts and viral load were an indicator for HIV/HCV coinfections. Socio-demographic variables were not associated (p > 0.05) with HIV/HCV coinfection in univariate analysis; older PLWHA were more likely to be HCV-positive. Males were more prone to HIV/HCV coinfection than females. HIV status did seem to influence the predisposition to HCV infection, as an increase in susceptibility was observed with HIV-infected patients in Yenagoa, Nigeria. The high prevalence of HIV/HCV coinfection in PLWHA in Yenagoa receiving ART demands routine screening for viral hepatitis coinfection, intensive prevention of childhood HCV transmission, and modification of the management of HIV infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of the University of Port Harcourt gave ethical approval for the study. The management of the Federal Medical Centre, Yenagoa, Nigeria gave administrative approval for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.